Factor | Multivariable p Value |
---|---|
(Intercept) | 0.578 |
OPRK1: rs702764: TC genotype | 0.038 |
OPRK1: rs702764: CC genotype | 0.997 |
HTR2A: rs6313: GA genotype | 0.008 |
HTR2A: rs6313: AA genotype | 0.456 |
DDC: rs383709: -/AGAG genotype | 0.01 |
DDC: rs3837091: -/- genotype | 0.043 |
DDC: rs1451375: CA genotype | 0.122 |
DDC: rs1451375: AA genotype | 0.037 |
ADRA2C: rs76337672: GC genotype | 0.705 |
ADRA2C: rs76337672: CC genotype | 0.995 |
DRD2: rs1800497: GA genotype | 0.655 |
DRD2: rs1800497: AA genotype | 0.993 |
Age | 0.071 |
Sex | 0.014 |
Dopamine agonist use | 0.001 |
Sets of variables were determined using stepwise regression. p Values for each variable were adjusted for the other covariates. Subgroup analysis was performed on 149 patients who either were on DA treatment or did not receive DRT during follow-up.
DA, dopamine agonist; DRT, dopamine replacement therapy; ICD, impulse control disorders.